Literature DB >> 8889222

Preliminary report of polymer-encapsulated dopamine-secreting cell grafting into the brain.

I Date1, Y Miyoshi, T Ono, T Imaoka, T Furuta, S Asari, T Ohmoto, H Iwata.   

Abstract

Polymer-encapsulated dopamine-secreting cell grafting is one of the most promising approaches for the treatment of Parkinson's disease. We microencapsulated dopamine secreting PC12 cells into agarose/poly(styrene sulfonic acid) complex and grafted them into the xenogeneic brain without immunosuppression. Dopamine secretion from the encapsulated cells was confirmed by high-performance liquid chromatography (HPLC) analysis before grafting. A large number of encapsulated PC12 cells survived in the brain 1 mo after transplantation and these cells were immunoreactive to tyrosine hydroxylase (TH) antibody, suggesting that these cells were secreting dopamine into the brain. There was no apparent immunological rejection or tumor formation. We concluded that microencapsulated PC12 cells survive in the xenogeneic brain without immunosuppression, and this grafting procedure is expected to be applied for the treatment of Parkinson's disease in the near future in combination with stereotaxic thalamotomy or pallidotomy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889222     DOI: 10.1016/0963-6897(96)00032-2

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  3 in total

Review 1.  Neural transplantation for Parkinson's disease.

Authors:  I Date; T Ohmoto
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

2.  A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons.

Authors:  M P Smidt; H S van Schaick; C Lanctôt; J J Tremblay; J J Cox; A A van der Kleij; G Wolterink; J Drouin; J P Burbach
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 3.  Personalized nanomedicine advancements for stem cell tracking.

Authors:  Miroslaw Janowski; Jeff W M Bulte; Piotr Walczak
Journal:  Adv Drug Deliv Rev       Date:  2012-07-20       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.